TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 7.10nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 8.20nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 9.40nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 12.3nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 13.7nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 18.4nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 19.9nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 21nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 21.5nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 24.1nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 25.2nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 30.7nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 31.4nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 33.4nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 45.2nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 53.6nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 55.2nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 70.9nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 73.2nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 76.9nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 185nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 208nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 288nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 343nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 568nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair























